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OBJECTIVES We investigated the impact of diabetes mellitus on myocardial perfusion after primary
percutaneous coronary intervention (PCI) utilizing myocardial blush grade (MBG) and
ST-segment elevation resolution (STR).
BACKGROUND Diabetes is an independent predictor of outcomes after primary PCI for acute myocardial
infarction (AMI). Whether the poor prognosis is due to lower rates of myocardial reperfusion
is unknown.
METHODS Reperfusion success in those with and without diabetes mellitus was determined by measuring
MBG (n  1,301) and STR analysis (n  700) in two substudies of the Controlled
Abciximab and Device Investigation to Lower Late Angioplasty Complications (CADIL-
LAC) trial among patients undergoing primary PCI for AMI.
RESULTS There were no differences between those with or without diabetes with regard to
postprocedural Thrombolysis In Myocardial Infarction (TIMI) flow grade 3 (95%),
distribution of infarct-related artery, and the frequency of stent deployment or abciximab
administration. Patients with diabetes mellitus were more likely to have absent myocar-
dial perfusion (MBG 0/1, 56.0% vs. 47.1%, p  0.01) and absent STR (20.3% vs. 8.1%,
p  0.002). Diabetes mellitus (hazard ratio [HR] 1.63 [95% confidence interval (CI) 1.17
to 2.28], p  0.004) was an independent predictor of absent myocardial perfusion (MBG
0/1) and absent STR (HR 2.94 [95% CI 1.64 to 5.37], p  0.005) by multivariate
modeling.
CONCLUSIONS Despite similar high rates of TIMI flow grade 3 after primary PCI in patients with and
without diabetes, patients with diabetes are more likely to have abnormal myocardial
perfusion as assessed by both incomplete STR and reduced MBG. Diminished micro-
vascular perfusion in diabetics after primary PCI may contribute to adverse
outcomes. (J Am Coll Cardiol 2005;45:508 –14) © 2005 by the American College of
ublished by Elsevier Inc. doi:10.1016/j.jacc.2004.10.054Cardiology Foundation
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phe major cause of morbidity and mortality in patients with
iabetes mellitus is cardiovascular disease (1,2). The pres-
nce of diabetes is an independent predictor of early and late
ortality after acute myocardial infarction (AMI) (2,3). The
igher mortality in AMI patients with versus without
iabetes may, in part, be due to more extensive coronary
therosclerosis and concomitant comorbid conditions, re-
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004, accepted October 26, 2004.uced cardiac reserve, and excessive delay from symptom
nset to presentation (4–6). Treatment of diabetes with
ulfonylurea oral hypoglycemic drugs may further diminish
he ability of the myocardium to tolerate ischemia (7).
iabetes has also been associated with abnormal coronary
ndothelial function, diminished coronary flow reserve, and
mpaired ischemic preconditioning (8–10), all of which may
esult in abnormal myocardial perfusion.
Recent small studies suggest that acute outcomes in
iabetic patients with AMI may be better after reperfusion
ith primary percutaneous coronary intervention (PCI)
han thrombolytic therapy (5,11). However, compared with
atients without diabetes, diabetics remain at increased risk
or adverse outcomes after primary PCI. Whether this is, in
art, due to abnormal myocardial perfusion after PCI in
atients with diabetes has not been formally studied. We,
herefore, examined the impact of diabetes mellitus on
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February 15, 2005:508–14 Myocardial Perfusion and Diabetesyocardial reperfusion from a large multicenter, prospective
tudy of primary PCI in AMI, utilizing two well-validated
easures of myocardial perfusion and reperfusion success,
esolution of ST-segment elevation (STR) (12–16) and the
yocardial blush grade (MBG) (17–20).
ETHODS
he details of the Controlled Abciximab and Device Inves-
igation to Lower Late Angioplasty Complications (CA-
ILLAC) trial protocol have been published previously
21). In brief, 2,082 patients of any age with AMI within
2 h of symptom onset undergoing primary PCI were
nrolled in 76 centers in nine countries between November
997 and September 1999, and randomized in a 2  2
actorial design to primary balloon angioplasty versus stent-
ng, with or without abciximab. The principal exclusion
riteria consisted of cardiogenic shock, saphenous vein graft
cclusion, and lesions otherwise not amenable to stent
mplantation. Clinical follow-up continued for one year.
An independent committee blinded to randomization
djudicated all primary end point events. Major adverse
ardiac events (MACE) were defined as a composite of
eath, reinfarction, ischemic-driven target vessel revascular-
zation, or disabling stroke as previously defined (21).
iabetic status was classified by treatment with diet alone,
ral hypoglycemic agents, and insulin. The principal clinical
esults of the CADILLAC trial stratified by diabetes have
een previously reported (22). The present analyses are
estricted to the impact of diabetes on myocardial perfusion
s assessed in formal STR and MBG substudies within the
ADILLAC trial.
BG substudy. Myocardial blush grade is an angio-
raphic surrogate of myocardial perfusion after PCI, and
trongly correlates with survival after reperfusion therapy in
MI (17–20). The details of the CADILLAC myocardial
lush substudy have been previously published (23). In brief,
yocardial blush in the distribution of the infarct vessel
fter PCI was analyzed using the methodology of van’t Hof
t al. (17) at an independent angiographic core laboratory at
he Cardiovascular Research Foundation in New York City
linded to clinical outcomes. Based on the maximal densi-
Abbreviations and Acronyms
AMI  acute myocardial infarction
CADILLAC  Controlled Abciximab and Device
Investigation to Lower Late Angioplasty
Complications trial
CI  confidence interval
HR  hazard ratio
MACE  major adverse cardiac events
MBG  myocardial blush grade
OR  odds ratio
PCI  percutaneous coronary intervention
STR  ST-segment resolutionometric degree of contrast opacification, MBG in 1,301 tatients was scored as MBG 0/1  no or minimal myocar-
ial contrast opacification; MBG 2  moderate contrast
pacification but less than in either an ipsilateral or con-
ralateral noninfarct artery; and MBG 3, normal myocardial
lush or contrast opacification, comparable with the other
oronary arteries. When myocardial blush persisted (“stain-
ng”), MBG-0 was assigned.
TR substudy. ST-segment monitoring is a well-validated,
oninvasive method for assessing the efficacy of myocardial
eperfusion therapy in patients with AMI (12–15), and STR
as been correlated with the restoration of epicardial and
icrovascular blood flow and myocyte function (16). The
ethodology of the CADILLAC STR substudy has also
reviously been reported (24). In brief, 700 patients who met
he following criteria were entered into a formal substudy to
xamine the impact of electrocardiographic STR after AMI: 1)
aired electrocardiograms (ECG) at baseline and within 4 h
fter PCI (mean 1.8  0.8 h) with 1 mm baseline ST-
egment elevation in two contiguous leads in the infarct
erritory; and 2) absence of conditions on both ECGs con-
ounding interpretation, including left bundle branch block,
acing, preexcitation, ectopy, missing leads, and artifact. ST-
egment resolution was measured at an independent core
lectrocardiographic laboratory (Beth Israel Deaconess Medi-
al Center, Boston, Massachusetts) blinded to clinical out-
omes. ST-deviation was measured with digital calipers to the
earest 0.01 mV. The summed level of ST-segment elevation
as calculated for anterior myocardial infarction in V1 to V6, I,
nd aVL, and for inferior myocardial infarction in leads II, III,
VF, V5, and V6. As per Schroder et al. (12), STR was
lassified as complete (70%), partial (30% to 70%), or absent
30%).
tatistical analysis. Categorical variables were compared
ith Fisher exact test for paired comparisons and the
hi-square test for trend for three-way comparisons. Con-
inuous variables are presented as medians and interquartile
anges, and were compared using the Kruskal-Wallis non-
arametric test. Adverse event rates during follow-up were
ummarized and displayed as Kaplan-Meier estimates and
ompared using the log-rank test. Stepwise logistic regres-
ion analysis was used to identify independent predictors of
bsent STR (30%) and absent or minimal blush (MBG
/1) after PCI. Baseline clinical, angiographic, and proce-
ural variables as seen in Tables 1 and 2 were included in the
ultivariate models with an entry and exit criteria of p 
.10. Cox proportional hazard regression was used to
dentify independent correlates of mortality in diabetics.
ESULTS
aseline characteristics. There were 232 (17.8%) diabetics
mong the 1,301 patients who were enrolled in the formal
BG substudy, and 118 (16.8%) diabetics among the 700
atients enrolled in the formal STR substudy. The clinical
haracteristics of patients with and without diabetes for the
wo substudies are summarized in Table 1. Patients with
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Myocardial Perfusion and Diabetes February 15, 2005:508–14iabetes were older, more likely to be female and have
ypertension and congestive heart failure at presentation,
nd presented later from the symptom onset, but were less
ikely to be current smokers. The differences in baseline
haracteristics are consistent with the diabetic status of the
atients and have been observed in previous studies (5);
owever, we cannot exclude selection bias resulting from a
ubgroup analysis. As seen in Table 2, diabetic patients were
ore likely to have multivessel coronary artery disease and
reprocedure Thrombolysis In Myocardial Infarction (TIMI)
Table 1. Baseline Characteristics Stratified by
MB
No Diabet
Number 1,069
Age, yrs 60 (50, 69
Male, % 74.5
Hypertension, % 44.1
Hypercholesterolemia, % 37.8
Current smoker, % 46.8
Peripheral vascular disease, % 2.4
Creatinine clearance 60 cc/min, % 18.9
Prior myocardial infarction, % 13.4
Prior coronary angioplasty, % 11.0
Prior bypass surgery, % 1.9
Killip class 2/3, % 8.9
Symptoms to hospital arrival, h 1.8 (1.0, 3.
Symptoms to angioplasty, h 4.0 (2.9, 6.
Insulin therapy, % —
*p  0.05. †p  0.01. ‡p  0.001.
MBG  myocardial blush grade; STR  ST-segment re
Table 2. Angiographic and Procedural Data St
MBG Su
No Diabetes
Baseline ejection fraction, % 50 (40, 56)
Number of diseased vessels, %
One 53.4
Two 32.0
Three 14.6
Infarct vessel, %
Left anterior descending 35.6
Right coronary artery 45.8
Circumflex artery 18.1
TIMI flow (% of patients)
Preprocedure
Grade 0/1 70.8
Grade 2 9.6
Grade 3 19.6
Postprocedure
Grade 0/1 1.1
Grade 2 2.5
Grade 3 96.3
Reference diameter (mm) 2.95 (2.61, 3.33)
Diameter stenosis (%)
Preprocedure 100 (77.3, 100)
Postprocedure 17.9 (9.1, 26.9)
Stent implantation, % 56.3
Abciximab administered, % 51.6*p  0.05. †p  0.01. ‡p  0.001.
TIMI  Thrombolysis In Myocardial Infarction; other abbreviow grade 3 than nondiabetic patients. There were no differ-
nces in the distribution of the infarct-related artery, reference
essel diameter, severity of stenosis, rates of stent implantation
r abciximab administration, or postprocedural TIMI flow
rade 3 between diabetic and nondiabetic patients.
BG and STR after PCI in diabetes. There was no
ifference in the prevalence of diabetes among the patients
ho were and those who were not included in the MBG
nd STR subanalyses in the CADILLAC trial (23,24). As
een in Figure 1, absent myocardial perfusion (MBG 0/1)
etic Status
bstudy STR Substudy
Diabetes No Diabetes Diabetes
232 582 118
62 (55, 70)† 59 (49, 68) 62 (55, 70)†
59.9‡ 75.1 66.1
66.4‡ 44.8 58.5†
44.4 36.8 34.7
31.0‡ 46.4 38.1
3.0 1.9 6.8†
22.5 17.0 22.6
17.2 11.3 14.4
12.0 9.3 8.5
4.3* 1.2 1.7
16.0† 8.5 11.9
2.1 (1.2, 4.4)* 1.5 (1.0, 2.8) 2.0 (1.1, 3.2)*
4.9 (3.3, 7.4)‡ 3.4 (2.7, 5.0) 4.0 (2.9, 5.6)*
22.4 — 14.4
n.
ed by Diabetic Status
y STR Substudy
iabetes No Diabetes Diabetes
(40, 60) 48 (40, 55) 47 (35, 55)
40.9‡ 56.4 40.7†
37.5 31.3 37.3
21.6* 12.4 22.0†
33.6 43.6 39.0
50.9 43.6 51.7
15.5 12.5 9.3
57.1‡ 74.7 60.3†
10.4 10.2 14.7
32.5‡ 15.1 25.0*
1.7 1.2 1.7
2.6 2.8 2.6
95.7 96.0 95.7
(2.59, 3.25) 2.97 (2.62, 3.41) 2.96 (2.62, 3.30)
(69.2, 100) 100 (79.6, 100) 100 (73.0, 100)
(8.9, 25.2) 18.2 (8.5, 27.7) 17.4 (10.1, 24.9)
57.3 56.5 56.8
56.5 50.9 50.0Diab
G Su
es
)
6)
2)ratifi
bstud
D
50
2.86
100
17.5ations as in Table 1.
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February 15, 2005:508–14 Myocardial Perfusion and Diabetesfter primary PCI was significantly more common in
iabetic compared with nondiabetic patients. By multivar-
ate analysis, diabetes (odds ratio [OR] 1.63 [95% confi-
ence interval (CI) 1.17 to 2.28], p  0.004), anterior
nfarction (OR 4.14 [95% CI 3.18 to 5.4], p 0.0001), and
rolonged time from symptom onset to angioplasty (OR
.07 [95% CI 1.03 to 1.11], p  0.0008) were independent
redictors of absent postprocedural myocardial perfusion.
Absent STR was also significantly more frequent in
atients with compared to those without diabetes (Fig. 2).
y multivariate analysis, diabetes (OR 2.94 [95% CI 1.60 to
.37], p  0.0005), anterior infarction (OR 3.98 [95% CI
.21 to 7.17], p  0.0001), and prolonged time from
ymptom onset to angioplasty (OR 1.11 [95% CI 1.04 to
.19], p  0.002) were independent predictors of absent
TR.
linical implications of myocardial perfusion after pri-
ary PCI in patients with diabetes. There was an inverse
elationship between MBG and mortality in diabetic pa-
ients, both at 30 days and 1 year, though this relationship
as not statistically significant (Fig. 3). By multivariate
nalysis, lower creatinine clearance (hazard ratio [HR] 1.06
95% CI 1.03 to 1.11], p  0.0003) was the only indepen-
igure 1. Myocardial perfusion grade after intervention in patients with
nd without diabetes.i
igure 2. ST-segment resolution after intervention in patients with and
ithout diabetes.ent predictor of 30-day mortality in patients with diabetes
n this substudy. Absent MBG was not significantly predic-
ive of mortality when forced into this model (HR 1.67
95% CI 0.33 to 8.44], p  0.54). Reduced creatinine
learance (HR 1.03 [95% CI 1.01 to 1.04], p  0.008) and
dmission Killip class 2/3 (HR 3.63 [95% CI 1.27 to 10.42],
 0.02) were independent predictors of one-year mortal-
ty. In this model the MBG HR for one-year mortality was
.05 (95% CI 0.86 to 10.84, p  0.08).
As seen in Figure 4, absent STR was a statistically
ignificant univariate predictor of mortality in diabetic
atients. By multivariate analysis in this substudy, lower
reatinine clearance (HR 1.16 [95% CI 1.03 to 1.29], p 
.01) was the only independent predictor of 30-day mor-
ality in diabetics. Absent STR was weakly predictive of
0-day mortality when forced into this model (HR 11.04
0.70 to 165.60], p  0.08). However, absent STR was a
tatistically significant independent predictor of one-year
ortality in diabetic patients (HR 11.71 [95% CI 1.53 to
9.90], p  0.02), as was reduced creatinine clearance (HR
.09 [95% CI 1.03 to 1.14], p  0.02) and the presence of
riple-vessel disease (HR 9.90 [95% CI 1.31 to 75.05], p 
.03).
ISCUSSION
he major findings of the present study are: 1) despite
imilar rates of TIMI flow grade 3 after primary PCI in
atients with and without diabetes, patients with diabetes
re more likely to have abnormal myocardial perfusion as
ssessed by both incomplete STR and reduced MBG; and
) diminished microvascular perfusion in diabetics after
rimary PCI may contribute to the increased mortality rates
n these patients.
Despite the effective restoration of normal epicardial flow
ates in 95% of patients with diabetes in this study,
omplete resolution of ST-segment elevation was observed
n only approximately half of the patients. Similarly, only
pproximately half of patients had normal myocardial per-
usion as assessed angiographically by the MBG. By mul-
ivariate analysis, the presence of diabetes (as well as anterior
MI and delayed reperfusion) was an independent predic-
or of both absent STR and a closed microvasculature.
Few prior reports have examined myocardial perfusion in
iabetic patients after reperfusion therapy. In a previous
tudy examining pooled data from four TIMI trials, com-
lete STR at 90 min tended to be less often present in
atients with diabetes, but only in those without TIMI flow
rade 3 (25). A lower likelihood of early STR, defined as
50% decrease in ST-segment elevation at 30 min, has
een reported from a small study in insulin-requiring
iabetics after primary PCI (26). The results of the present
ulticenter study thus confirm and extend the findings from
hese studies in demonstrating impaired myocardial perfu-
ion in a relatively large diabetic cohort after primary PCI,
ndependent of epicardial flow rates.
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Myocardial Perfusion and Diabetes February 15, 2005:508–14Persistent ST-segment elevation and abnormal myocar-
ial blush in the presence of normal epicardial blood flow
re indicative of diminished microvascular blood flow and
mpaired tissue perfusion, often referred to as the “no-reflow
henomenon” (27,28). Thus, our findings confirm that
yocardial microvascular flow is more frequently impaired
n diabetes. Impaired myocardial reperfusion as evidenced
y diminished STR and abnormal MBG after reperfusion
herapy is a powerful predictor of decreased left ventricular
unctional recovery and greater infarct size (27,29,30), as
ell as short- and long-term mortality (12,13,15,20,23,24).
hus, abnormal myocardial perfusion may, in part, explain
he poor prognosis in patients with, compared to those
ithout, diabetes after primary PCI (31). Our study also
onfirms the utility of electrocardiographic STR and MBG
n predicting mortality in diabetic patients treated with PCI.
negative stepwise relationship between the magnitude of
TR and MBG, and 30-day and 1-year mortality was
ound. In the current study, STR was more useful than
BG in predicting long-term outcomes in diabetics. How-
ver, given the fact that the present report was based on
ifferent groups of patients in two separate substudies,
igure 3. Relationship between myocardial blush grade and 30-day (left) a
1,069).igure 4. Relationship between the ST-segment resolution and 30-day (left) an
n  582).dditional large-scale studies are required to examine the
elative prognostic utility of STR and MBG.
While the precise pathophysiologic mechanisms by
hich diabetes contributes to microvascular injury remain
nknown, several potential explanations have been postu-
ated. First, diabetes is associated with a prothrombotic and
nflammatory state; microthrombi and leucocyte accumula-
ion in the capillaries of diabetic patients may, thus, lead to
oronary microvascular obstruction (32,33). Second, coro-
ary endothelial and smooth muscle dysfunction due to
xidative stress accompanied by reduced nitric oxide bio-
vailability and increased endothelin release may lead to
icrovascular spasm and reduce myocardial perfusion after
CI in diabetic patients (33). Third, the acute recruitment
f coronary collaterals appears to be impaired in diabetic
ompared with nondiabetic patients (34). These observa-
ions require validation, and further studies are needed to
lucidate the mechanisms of microvascular hypoperfusion in
iabetics with the aim of developing new therapies.
tudy limitations. The current analyses, as post-hoc anal-
ses of two substudies, are subject to both recognized and
nknown biases; STR and MBG were the only markers of
year (right) mortality in patients with (n  232) and without diabetes (nnd 1-d 1-year (right) mortality in patients with (n  118) and without diabetes
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February 15, 2005:508–14 Myocardial Perfusion and Diabetesyocardial perfusion examined in the present study. Other
maging modalities of microcirculatory function such as
ontrast echocardiography, positron emission tomographic
canning, and invasive measures of coronary flow reserve
Doppler) may provide additional insights regarding micro-
irculatory function in the diabetic patient with AMI after
eperfusion. An interaction between insulin therapy and
yocardial perfusion could not be determined due to the
elatively small number of insulin-treated patients included
n the analyses. The use of coronary stent has increased
ignificantly since this study was conducted, which may
imit the applicability of our findings to current practice.
owever, recent data suggests that stent deployment does
ot alter myocardial perfusion (23,24). The present study
xamined the impact of myocardial perfusion on mortality
nly; the impact of diabetes and microcirculatory function
n myocardial salvage and recovery of left ventricular
unction was not studied. Finally, while CADILLAC is the
argest multicenter trial of primary PCI to date, significantly
arger, specifically designed studies are required to compre-
ensively evaluate all the variables responsible for the
dverse prognosis in diabetic patients with AMI.
onclusions and clinical implications. With contempo-
ary interventional approaches, the procedural success rate
f primary PCI in diabetics with AMI is equivalent to
ondiabetic patients. However, a greater proportion of
iabetic than nondiabetic patients fail to achieve normal
yocardial perfusion, a finding associated with higher
ortality in this patient cohort. Additional research is
equired to develop novel device-based and pharmacologic
pproaches to enhance microcirculatory function after pri-
ary PCI, which may improve the prognosis of patients
ith diabetes and AMI. In this regard, assessment of STR
nd MBG after reperfusion are relatively simple, noninva-
ive methods with prognostic utility beyond TIMI flow
rade 3, and, as such, should be included in future studies of
eperfusion.
eprint requests and correspondence: Dr. Gregg W. Stone,
he Cardiovascular Research Foundation, Columbia University
edical Center, Herbert Irving Pavilion, 5th Floor, 161 Fort
ashington Avenue, New York, New York 10032. E-mail:
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